| Name | Title | Contact Details |
|---|---|---|
Allan Thoen |
Director and Associate General Counsel | Profile |
Leo Bronfman |
VP and Global Head Legal Portfolio | Profile |
Josephine Liu |
Global Head of IP Litigation | Profile |
Nicholas Tantillo |
Vice President, Regulatory Affairs | Profile |
Mikaella Gorelik |
Executive Director, Business Development and Licensing | Profile |
Laboratory Technologies is a Maple Park, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker`s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient`s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ to improve the ability of the cellular immune system to recognize and destroy diseased cells.
Global Pharmaceutical Corp is a Chalfont, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bloomios is a U.S. based leading hemp and nutraceutical GMP manufacturer specializing in product development, formulation, packaging, and design. They provide white label and private label services for businesses looking to expand into the hemp industry.
Adherium (ASX.ADR) is a global leader in digital health technologies which address sub-optimal medication use in chronic disease.